R Bergman1, M Parkes. 1. Department of Gastroenterology, Addenbrooke's Hospital, Cambridge, UK.
Abstract
BACKGROUND: Mesalazine is among the medications most commonly prescribed by gastroenterologists, having to a large extent superseded sulfasalazine (sulphasalazine). However, there are still a number of aspects regarding its use which provoke debate and controversy. AIM: To provide a systematic assessment of the evidence for the use of mesalazine in ulcerative colitis and Crohn's disease. METHODS: References were identified using PubMed database. Additional references were identified with related article searches. RESULTS: Mesalazine has a clear role in the maintenance of remission in ulcerative colitis and management of mild to moderately active disease, although the efficacy of topical preparations or combined topical and oral is clearly superior to oral alone. Evidence that increasing the dose of oral mesalazine improves efficacy is not clear-cut. The benefits of mesalazine in the management of acute Crohn's disease and the maintenance of remission are questionable and alternative treatments are usually more appropriate. Emerging evidence suggests that maintenance mesalazine reduces the risk of neoplastic progression in chronic ulcerative colitis. Compliance with therapy is thus important, as is an understanding of individuals most likely to default on this. CONCLUSION: Evidence for a beneficial effect of mesalazine is largely confined to the management of ulcerative colitis.
BACKGROUND:Mesalazine is among the medications most commonly prescribed by gastroenterologists, having to a large extent superseded sulfasalazine (sulphasalazine). However, there are still a number of aspects regarding its use which provoke debate and controversy. AIM: To provide a systematic assessment of the evidence for the use of mesalazine in ulcerative colitis and Crohn's disease. METHODS: References were identified using PubMed database. Additional references were identified with related article searches. RESULTS:Mesalazine has a clear role in the maintenance of remission in ulcerative colitis and management of mild to moderately active disease, although the efficacy of topical preparations or combined topical and oral is clearly superior to oral alone. Evidence that increasing the dose of oral mesalazine improves efficacy is not clear-cut. The benefits of mesalazine in the management of acute Crohn's disease and the maintenance of remission are questionable and alternative treatments are usually more appropriate. Emerging evidence suggests that maintenance mesalazine reduces the risk of neoplastic progression in chronic ulcerative colitis. Compliance with therapy is thus important, as is an understanding of individuals most likely to default on this. CONCLUSION: Evidence for a beneficial effect of mesalazine is largely confined to the management of ulcerative colitis.
Authors: José Ferrusquía; Isabel Pérez-Martínez; Ricardo Gómez de la Torre; María Luisa Fernández-Almira; Ruth de Francisco; Luis Rodrigo; Sabino Riestra Journal: World J Gastroenterol Date: 2015-04-07 Impact factor: 5.742
Authors: Brennan M R Spiegel; Wayne Ho; Eric Esrailian; Stephan Targan; Peter D R Higgins; Corey A Siegel; Marla Dubinsky; Gil Y Melmed Journal: Clin Gastroenterol Hepatol Date: 2008-09-04 Impact factor: 11.382
Authors: Emilio G Quetglas; Zlatan Mujagic; Simone Wigge; Daniel Keszthelyi; Sebastian Wachten; Ad Masclee; Walter Reinisch Journal: World J Gastroenterol Date: 2015-11-28 Impact factor: 5.742